To determine whether ␣-fetoprotein (AFP)-regulated ribonucleotide reductase (RR) production would promote more vigorous and specific viral killing in AFP-expressing hepatocellular carcinoma (HCC). Background: AFP is expressed in over 70% of primary HCC but not in normal adult liver. AFP production by HCC can be exploited to target viral killing of tumor cells. G207 is an oncolytic herpes virus lacking UL39, the gene encoding RR. RR is an enzyme required for viral DNA synthesis and cytotoxicity. Methods: Enzyme-linked immunosorbent assay (ELISA) was performed for AFP levels on Hep3B and PLC5 human HCC cells. An AFP-albumin enhancer-promoter complex (AFP-alb) was constructed in a luciferase vector to assess function. AFP-alb was cloned upstream of UL39 (AFP-alb/UL39) and transfected into HCC cells for G207 cytotoxicity assays. Viral plaque forming assays evaluated G207 replication. Hep3B flank tumors, with and without AFP-alb/UL39 transfection, were established in athymic mice (n ϭ 28) and treated with G207. Results: Hep3B had 5-fold higher AFP levels than PLC5 (P Ͻ 0.00001). AFP-alb increased luciferase expression 72-fold in Hep3B (P Ͻ 0.001) and 3-fold in PLC5 (P Ͻ 0.001). AFP-alb/UL39 transfection increased G207 cytotoxicity 93% in Hep3B (P Ͻ 0.0005), with no significant increase in PLC5. Peak viral titers were 46-fold higher in Hep3B transfected with AFP-alb/UL39 versus mock-transfected cells (P Ͻ 0.01), with no significant change in PLC5. Flanks tumors transfected with AFP-alb/UL39 and treated with G207 demonstrated a 76% volume reduction versus mocktransfected tumors infected with G207 (P Ͻ 0.0001). Conclusions: AFP-driven RR production by hepatoma cells significantly enhances herpes viral cytotoxicity and specificity in vitro and reduces tumor burden in vivo.
T umor-associated antigens such as ␣-fetoprotein (AFP) may be used as targets for cancer selective gene therapy. The AFP gene is highly expressed in the fetal liver but transcriptionally silent in normal adult hepatocytes. However, more than 70% of hepatocellular carcinomas (HCC) demonstrate reactivation of this oncofetal protein. 1 AFP is thus present in the fetus, absent in the normal healthy adult, and re-expressed in cancers such as primary HCC. Widespread disease at the time of diagnosis and associated cirrhosis often preclude curative treatments for hepatoma. 2 New therapeutic strategies directed to HCC are necessary. AFP expression by primary liver tumors may allow for selective delivery of anticancer agents. The role of AFP as a potential gene therapy target has recently been studied. 2, 3 First described in 1956, this tumor-associated antigen has undergone intense molecular characterization. AFP is a V-shaped, 70-kDa glycoprotein found both intra-and extracellularly. AFP is highly expressed in the fetal liver and gastrointestinal tract, where it may serve as a metabolic transporter for fatty acids. 4 The transcriptional factors that drive AFP expression have not been entirely elucidated. Several nonspecific regulators that bind to elements in the promoter and enhancer regions of the AFP gene have been identified. These factors, such as fetoprotein transcription factor, SF1, and Nkx2.8, may play a role in AFP gene transcription in both fetal and cancer tissues. 5 The AFP promoter, upstream AFP enhancers, and silencer regions all interact to regulate the degree of AFP gene expression and resulting glycoprotein production. The AFP enhancer though controls 98% of inducible AFP transcription, whereas the AFP promoter has demonstrated weak activity. 6 In contrast, the albumin promoter has strong intrinsic activity, and its use in combination with the AFP enhancer to drive paired gene transcription in HCC has been documented. 3 This AFP enhancer-albumin promoter complex (AFP-alb) may therefore be used to target therapeutic genes to AFP-secreting cancers.
Mutant herpes simplex viruses (HSV) are a novel therapy for HCC. These genetically engineered viruses specifically infect, replicate within, and lyse tumor cells. HSV have been mutated to reduce their virulence and attenuate their ability to infect normal tissues. G207 is an oncolytic HSV that contains deletions in both copies of ␥ 1 34.5, a gene necessary for central nervous system infection. It also contains an inactivating insertion within UL39, the gene which encodes the large subunit of ribonucleotide reductase (RR). 7 RR is a critical, rate-limiting enzyme that regulates viral DNA synthesis and replication. To progress through its lytic cycle, G207 relies on exogenous RR provided by rapidly dividing tumor cells. 8 Without this cellular supply of RR, G207 would be ineffective as a cancer-killing agent.
In these experiments, we sought to determine whether RR expression driven by an AFP-alb enhancer-promoter complex would improve G207 cytotoxicity and specificity, in AFP-producing HCC cells.
MATERIALS AND METHODS

Cell Culture
Hep3B and PLC5 are well-described human HCC cell lines. These cell lines were obtained (American Type Culture Collection, Manassas, VA), maintained in a 5% CO 2 humidified incubator at 37°C, and subcultured twice a week. Hep3B and PLC5 cells were grown in minimum essential medium supplemented with 10% fetal calf serum. After plating and transfection procedures, cells were routinely incubated for 12 hours prior to viral infection to allow for attachment.
AFP Expression
Hep3B and PLC5 cells were plated at 5 ϫ 10 6 cells/ dish in 100 mm culture dishes (Costar, Corning Inc, Corning, NY). Following a 48-hour incubation, cells were washed twice with 20 mL of phosphate-buffered saline (PBS), lysed with 3ϫ cell lysis buffer (Cell Signaling Technology, Beverly, MA), and sonicated. Cellular debris was pelleted in a microcentrifuge (Brinkman 5415C, Westbury, NY) at 14,000 rpm for 5 minutes at 4°C. Protein content of the supernatant was determined according to the Bradford method (BioRad Protein Assay Reagent, Hercules, CA) by measuring absorbance at 595 nm (Beckman DU 640 spectrophotometer, Fullerton, CA). AFP enzyme-linked immunosorbent assay (ELISA, Alpha Diagnostic International, San Antonio, TX) was performed on 100 g of cellular protein from each sample.
AFP-alb Enhancer-Promoter Construction and Functional Assay
The human AFP enhancer was obtained in a bacterial plasmid (Invivogen, San Diego, CA). The 1756 base pair AFP enhancer sequence was amplified by polymerase chain reaction (PCR) using forward (5Ј-CTGTGTGCACTTTGTG-GCAGAGGAGC-3Ј) and reverse (5Ј-GCAAGCACTAGTG-GCCTGGATAAAGCTG-3Ј) primers (Invitrogen, Carlsbad, CA). These primers maintained a unique PstI restriction sequence upstream and introduced a unique SpeI restriction sequence downstream of the AFP enhancer. The 206-base-pair albumin promoter paired with an SV40 enhancer was obtained in a bacterial plasmid (Invivogen). The SV40 enhancer sequence was removed by restriction digest with PstI and SpeI (New England Biolabs (NEB), Beverly, MA), and the AFP enhancer was then ligated between these sites using Quick Ligase (NEB). The newly formed AFP-alb enhancerpromoter complex was removed by restriction digest with PstI and NcoI (NEB), and the PstI site was blunted by exonuclease digestion (Klenow, NEB). The pGL3 promoter vector (Promega, Madison, WI), which expresses luciferase, was digested with MluI and NcoI (NEB) to remove its native promoter region. The MluI end was blunted through exonuclease digestion (Klenow, NEB), and AFP-alb was cloned between the MluI and NcoI sites forming the luciferase reporter plasmid AFP-alb/pGL3 ( Fig. 1A, B ).
Hep3B and PLC5 cells were plated at 1.5 ϫ 10 6 cells/well in 6-well flat-bottom plates (Costar, Corning Inc). Cells were transfected with 1.8 g of the AFP-alb/pGL3 plasmid using Lipofectamine 2000 (Invitrogen). The native pGL3 promoter plasmid was used as a control in these experiments. Following incubation for 24 hours, cell lysates were collected and a luciferase assay (Luciferase Assay Kit, Promega) was performed using a single injection luminometer (Berthold Technologies MicroLumat Plus, Oak Ridge, TN). Protein concentrations of cell lysates were determined by Bradford's method (BioRad) to normalize luciferase activity between transfected groups.
Construction of Vector Expressing UL39
A plasmid containing the intact UL39 gene was a kind gift from Medigene Inc (San Diego, CA). The translated UL39 sequence was PCR amplified using Herculase Hotstart polymer- ase (Stratagene, La Jolla, CA) with forward (5Ј-GCATAGCT-GAAGCTTCTGTTGAAATGGCCAGCCG-3Ј) and reverse (5Ј-TCCACGTATCTAGAATCTGGATCGCCAGGTCCG-3Ј) primers (Invitrogen). These primers introduced a unique upstream HindIII restriction site, as well as a unique downstream XbaI site, while excluding the native UL39 promoter and poly-A tail. AFP-alb/pGL3 was digested with HindIII and XbaI (NEB) to remove the luciferase gene. The UL39 gene was then ligated between the HindIII and XbaI sites (Quick Ligase, NEB), forming the AFP-alb/UL39 plasmid (Fig. 1C ). The sequence was confirmed by PCR screen and restriction digests.
G207 Virus
G207, a generous gift from Medigene Inc, is a multimutated HSV containing deletions in both copies of the ␥ 1 34.5 neurovirulence gene. As an additional safety feature, the UL39 gene is inactivated by an insertional mutation with a functional lacZ reporter gene.
In Vitro Cytotoxicity of G207
Hep3B and PLC5 cells were plated at 1.5 ϫ 10 6 cells/well in 6-well flat-bottom plates (Costar, Corning Inc). Cells were transfected with 1.8 g of AFP-alb/UL39 plasmid DNA using Lipofectamine 2000 (Invitrogen). Control cells underwent mock transfection with Lipofectamine 2000 (Invitrogen) alone. The following day, cells were replated at 1 ϫ 10 5 cells/well in 24-well flat-bottom plates (Costar, Corning Inc). After a 12-hour incubation, Hep3B cells were infected with G207 at a multiplicity of infection (MOI: number of viral plaque forming units ͓PFU͔ per tumor cell) of 0.001 and PLC5 cells at 0.01. Each viral dose chosen represented the amount of virus required to elicit mild to moderate cytotoxicity for each cell line. G207 oncolysis was then determined by measuring the release of cytoplasmic lactate dehydrogenase (LDH) from surviving cells over 10 days. Cells were washed with PBS and lysed with 1.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO). LDH was quantified with a Cytotox 96 nonradioactive cytotoxicity assay (Promega), measuring the conversion of a tetrazolium salt into a red formazan product. Absorbance was measured at 450 nm with a microplate reader (EL312e, Bio-Tek Instruments, Winooski, VT). Cytotoxicity is expressed as the percentage of LDH activity in treated cells relative to mock-infected cells. All samples were tested in triplicate.
In Vitro Viral Replication
Following G207 infection, media was collected from the same sample wells that were used in the cytotoxicity assays. Confluent Vero cells (African green monkey kidney cells) were infected with this medium, and standard viral plaque forming assays were performed in triplicate.
Establishment and Treatment of Flank Tumors
All animal procedures were performed with the approval of the Memorial Sloan-Kettering Institutional Animal Care and Use Committee. Six-week-old, male nude mice were obtained (Charles River Laboratories, Wilmington, MA). Mice were anesthetized with intraperitoneal injection of ketamine and xylazine (100 mg/kg ketamine, 10 mg/kg xylazine) for all procedures. Mice were housed 3 per cage and allowed food and water ad libitum.
Hep3B cells were plated at 1.5 ϫ 10 6 cells/well in 6-well flat-bottom plates (Costar, Corning Inc). Cells were transfected with 1.8 g of AFP-alb/UL39 plasmid DNA using Lipofectamine 2000 (Invitrogen) and control cells underwent mock transfection. After a 12-hour incubation, cells were harvested, counted, and resuspended (1 ϫ 10 6 cells/50 L). Fourteen athymic mice underwent bilateral subcutaneous flank injections with 1 ϫ 10 6 Hep3B cells, which had received AFP-alb/UL39 transfection (n ϭ 14) or mock transfection (n ϭ 14). The following day, half the tumors from each group (n ϭ 7) were injected with 5 ϫ 10 3 PFU of G207 in 50 L of PBS or 50 L of PBS alone. The flank tumors of each animal received the same treatment. Tumor volumes were assessed over 2 weeks.
Statistical Analysis
Data are expressed as the mean Ϯ SD. Comparisons between groups were performed with a 2-tailed Student t test.
RESULTS
AFP Expression
Hep3B and PLC5 cells were examined for AFP expression by ELISA. Hep3B cell lysates had a mean AFP concentration of 32 IU/ml, and PLC5 cell lysates had an average concentration of 6 IU/ml. The 5-fold higher AFP levels expressed by Hep3B cells were statistically significant (P Ͻ 0.00001, Fig. 2 ).
Luciferase Activity
AFP-alb function was assessed by luciferase reporter assay. Following transfection with AFP-alb/pGL3, cell lysates underwent analysis for luciferase expression. Hep3B cells transfected with AFP-alb/pGL3 resulted in a 72-fold increase in luciferase activity versus cells transfected with pGL3 alone (P Ͻ 0.001, Fig. 3 ). In PLC5 cells, AFP-alb/ pGL3 transfection resulted in a 3-fold increase in luciferase activity compared with pGL3 alone (P Ͻ 0.001, Fig. 3 ). These experiments demonstrate that the AFP-alb complex significantly improved paired gene expression, particularly in AFP-expressing HCC cells.
In Vitro Cytotoxicity of G207
Hep3B and PLC5 cell viabilities were measured by cytotoxicity assay to determine viral oncolysis following AFP-alb/UL39 transfection. Hep3B cells transfected with AFP-alb/UL39 were more susceptible to G207 cell kill compared with mock-transfected cells. Three days after G207 Annals of Surgery • Volume 240, Number 4, October 2004 AFP and Oncolytic Viral Therapy infection, there was a 10% increase in cytotoxicity with AFP-alb/UL39 transfection, which was statistically significant (P Ͻ 0.05). This increase in G207 cytotoxicity improved to 83% by day 5 (P Ͻ 0.0001), 92% by day 7 (P Ͻ 0.0001), and 93% by day 10 after infection (P Ͻ 0.0005, Fig. 4A ). Hep3B cells that underwent mock transfection were resistant to G207 oncolysis, with no cell kill over 10 days. Cell survival in this group was not significantly different from control cells without G207 infection. PLC5 cells transfected with AFP-alb/UL39 did not demonstrate improved G207 cytotoxicity compared with PLC5 cells that underwent mock transfection. Ten days after G207 infection, there was a 50% to 60% cell kill in both the AFP-alb/UL39-transfected and mock-transfected PLC5 groups (P ϭ NS, Fig. 4B ). These results demonstrate that AFP-alb-driven RR production can significantly improve G207 cytotoxicity, specifically in AFP-producing HCC cells.
In Vitro Viral Replication
In Hep3B cells, the peak viral titer of mock-transfected cells was 5 ϫ 10 2 PFU. The peak viral titer of AFP-alb/ UL39-transfected Hep3B cells was 2.3 ϫ 10 4 PFU, representing a 230-fold increase over the initial infecting dose (1 ϫ 10 2 PFU) and a 46-fold increase over the peak titer of mock-transfected cells (P Ͻ 0.01, Fig. 5A ). In PLC5 cells, peak G207 titers were 9 ϫ 10 4 PFU for AFP-alb/UL39transfected cells and 8.7 ϫ 10 4 PFU for mock-transfected cells (P ϭ NS, Fig. 5B ). These results demonstrate that AFP-alb/UL39 significantly increases G207 replication in AFP-expressing HCC.
Inhibition of Tumor Growth
Hep3B cells, transfected with AFP-alb/UL39 or no DNA, were injected subcutaneously into the flanks of athymic mice to create an in vivo tumor model. Two weeks after tumor implantation, mice receiving mock-transfected Hep3B cells had a mean tumor volume of 155.4 Ϯ 33.3 mm 3 when treated with G207 and 171.7 Ϯ 34.5 mm 3 when treated with PBS, which were not significantly different. However, combining AFP-alb/UL39 transfection with G207 therapy resulted in a mean tumor volume of 36.5 Ϯ 7.6 mm 3 , which represented a 76% decrease in tumor volume compared with mock-transfected tumors receiving G207 alone (P Ͻ 0.0001, Fig. 6 ).
DISCUSSION
G207 is a multimutated herpes oncolytic virus that has been evaluated in phase I clinical trials. An inactivation at the UL39 gene locus makes G207 complementary to rapidly proliferating cancer cells which provide adequate cellular levels of RR. Mutant HSV deficient in RR have been shown to preferentially infect cancer cells while sparing normal tissues. 7 Through this UL39 mutation and other genomic deletions, the virulence of G207 has been attenuated. Induc-FIGURE 3. A luciferase assay evaluated AFP-alb enhancerpromoter function. After cloning into the pGL3 luciferase vector (Promega, Madison, WI), Hep3B and PLC5 cells were transfected with 1.8 g of our AFP-alb/pGL3 construct. After a 24-hour incubation, luciferase assay was performed (Luciferase Assay Kit, Promega, Madison, WI). The native pGL3 promoter plasmid was used as a control. There was a 72-fold increase in luciferase activity in Hep3B cells (P Ͻ 0.001) and a 3-fold increase in PLC5 cells (P Ͻ 0.001).
FIGURE 2.
Hep3B and PLC5 human hepatocellular carcinoma cells were assessed for AFP expression. Whole-cell lysates were obtained and AFP enzyme-linked immunosorbent assay was performed (Alpha Diagnostic International, San Antonio, TX) on 100-g protein samples from each cell line. AFP levels were 5-fold higher in Hep3B cells compared to PLC5 (P Ͻ 0.00001).
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Annals of Surgery • Volume 240, Number 4, October 2004 tion of UL39 transcription by a tumor-specific promoter, such as AFP, may therefore improve the specificity and oncolytic properties of G207. The transcriptional activity of the AFP gene decreases 1000-fold shortly after birth. 9 However, AFP expression is reactivated in the majority of HCC, and has thus been investigated as a means of targeting cancer therapy. Recent studies have paired the AFP enhancer-promoter with chemotherapeutic pro-drugs and suicide genes to direct these therapies to AFPproducing HCC cells. By utilizing an adenoviral vector expressing the cytosine deaminase gene, AFP-producing HCC cells 
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AFP and Oncolytic Viral Therapy could be selectively killed by 5-fluorocytosine administration. Another adenovirus expressing HSV thymidine kinase (tk) conferred gancyclovir sensitivity, specifically to AFPexpressing hepatoma cells. Furthermore, these approaches have demonstrated growth inhibition of AFP-producing human tumor xenografts. 10, 11 The sequences that regulate AFP gene transcription, including the enhancer and promoter regions, have been characterized. The AFP enhancer controls the majority of AFP gene expression, whereas the AFP promoter has demonstrated weak inducibility of the AFP gene. 6, 12 To overcome this weak promoter function, studies have combined the AFP enhancer with the active liver-specific albumin promoter to selectively target AFP-producing HCC. 3 The AFP and albumin proteins share a distant phylogenic relationship, with evolutionary divergence 300 to 500 million years ago. 13 However, the AFP and albumin genes remain in close phys-ical proximity on chromosome 4 in humans, 14 in rats, and 5 in mice. 14 The enhancer and promoter regions of the AFP and albumin genes are separated by only 30 kilobases, and the AFP enhancer can assist in regulating albumin expression. 2, 15, 16 The AFP enhancer paired exclusively with the albumin promoter has therefore been studied as a potential combination for strong transgene expression in AFP-secreting cancer cells. This AFP-alb complex has been used in targeting the cytokines IL-2 and IFN␣2b to AFP-expressing HCC through a retroviral vector. In that study, cytokine production positively correlated with cellular AFP expression, with resulting AFP-producing tumor xenografts demonstrating a significant reduction in volume compared with nontreated controls. 3 In addition, an adenovirus containing the AFP-alb complex paired with HSV-tk could transduce AFP-expressing HCC and inhibit tumor growth in vivo. 17 Our study further demonstrates the utility of the AFPalb regulatory complex in the treatment of HCC through a herpes oncolytic mutant. We constructed an AFP-alb complex that significantly improved paired transgene expression in high AFP-producing HCC cells. AFP-alb was then cloned upstream of UL39, the gene encoding the large subunit of RR, to up-regulate a critical enzyme required for viral DNA synthesis. UL39 expression under AFP-alb control significantly improved viral replication and cytotoxicity in HCC cells expressing high AFP levels. Viral replication and cytotoxicity were unchanged after AFP-alb/UL39 plasmid transfection in low AFP-expressing cells, further confirming the specificity of AFP-alb/UL39 function. High AFP-expressing HCC tumor xenografts were effectively treated with the combination of AFP-alb/UL39 and G207. This therapy resulted in a 76% reduction in tumor volume compared with G207 alone.
These experiments demonstrate a proof of principle that reintroducing UL39 under AFP-alb control in G207 can improve viral cytotoxicity and tumor selectivity in AFPsecreting HCC. These results encourage the construction of a recombinant G207 that autonomously expresses AFP-alb/ UL39. The replicative nature of this recombinant virus would amplify the UL39 gene product, creating an environment for more vigorous viral cytotoxicity. Furthermore, this genetically engineered virus would ultimately preclude the need for plasmid transfection and could be used as definitive treatment of established AFP-expressing HCC. FIGURE 6. The treatment of AFP-producing hepatocellular carcinoma flank tumors with G207 and AFP-alb/UL39 (n ϭ 7 per group). Athymic mice underwent flank injection with 1 ϫ 10 6 Hep3B cells that had undergone transfection with AFPalb/UL39 or no DNA. Tumor sites were re-injected with 5 ϫ 10 3 plaque forming units of G207 or phosphate-buffered saline (PBS). Following infection with G207, tumor volumes were assessed over 14 days. There was a 76% reduction in tumor volume with a combination of AFP-alb/UL39 transfection and G207 therapy (P Ͻ 0.0001). There was no significant difference among tumor volumes when given monotherapy with PBS, AFP-albUL39, or G207.
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Annals of Surgery • Volume 240, Number 4, October 2004 Discussions DR. STEVEN E. RAPER (PHILADELPHIA, PENNSYLVANIA): I am honored to review this work. Dr. Fong has expanded his studies on a genetically altered herpes virus, G207, by developing a method to further increase the specificity of targeting hepatoma cells for lysis. The gene for UL39, a ribonucleotide reductase required for replication of G207, was engineered to be turned on by a combination of a strong alpha-fetoprotein (AFP) enhancer, and a strong albumin promoter.
Many hepatocellular cancers express AFP, and Dr. Fong's technique allows the use of transcription factors responsible for the expression of AFP to also drive the UL39 gene. The result is a strategy of specific destruction of AFP expressing hepatocellular cancer cells.
Dr. Reinblatt in her presentation has provided data to support such a strategy, using two hepatoma cell lines, one which highly expresses AFP and one which doesn't. Introducing the UL39 gene driven by AFP/albumin and then infecting cells with the G207 herpes virus significantly kills AFP expressing tumor cells in vitro and in vivo. Further, as might be predicted, replication of G207 is seen.
I have several questions with regard to the work presented here. What percentage of tumor cells is transfected with the UL39 construct? A low percentage suggests a bystander effect might be occurring. Perhaps the authors could comment on such a possibility.
There are 2 controls not present in the manuscript. Were any studies done with an albumin UL39 construct without AFP enhancers? The strength of the albumin promoter could allow UL39 expression in the absence of requisite transcription factors. This would decrease the specificity of this approach, and adult liver certainly can express albumin.
Were normal hepatocytes used? As hepatocellular cancers are variable in levels of AFP expression, an unanswered question is whether there is a dose response or a threshold below which cellular AFP expression will not allow UL39 gene transcription. At a higher dose of vector, good tumor lysis is seen even in the low-AFP expressing cell line PLC5. A safety concern exists if a high enough dose of vector can overcome the lack of UL39. In permissive cells, as shown in today's presentation, replication of the herpes viral vector occurs. Replication will make dosing difficult if not impossible.
What do you think caused the residual tumors in your treated animals in the in vivo studies? Were these nontransfected cells, or do you think repeat dosing might be efficacious?
Are you aware of other tissue or cell specific enhancers turned on by fetoprotein transcription factor, SF1 or Nkx2.8? Again, this information would be important in the context of safety.
Lastly, your in vivo model involved UL39 gene transduction prior to implantation in animals. As it is unfeasible to translate your in vivo model directly into humans, how would you propose turning this concept into a clinical trial? I applaud Dr. Fong and his colleagues for their efforts to take elegant bench science to the bedside and then back to the bench. His approach exemplifies how we must cautiously but relentlessly move cellular and molecular medicine into the practice of surgery. Thank you for the privilege of the floor. The transcription factors such as fetoprotein transcription factor, SF1, as well as NKx2.8, are all related proteins which in humans have been found to enhance AFP gene transcriptions by binding to the AFP enhancer-promoter complex.
They are fairly specific, although FTF also regulates the synthesis of cholesterol-related genes such as 7-alpha hydroxylase. SF1, in addition to being present in hepatoma cells, has also been found in developing adrenals as well as gonads. And NKx2.8 is a recently identified protein that seems to be fairly specific to hepatoma cells.
These transcription factors have been evaluated only in AFP producing cells such as hepatocellular carcinoma and may not be found in hepatocytes; therefore, they are unlikely to drive other genes which would affect cytotoxicity genes.
In response to your question regarding the percentage of hepatocellular carcinoma cells which express AFP, it is thought that all hepatoma cells express AFP to some degree, some to higher levels, others to lower levels. Elevated serum levels of AFP are found in over 70% of patients with hepatoma, and 80% of primary hepatomas scan positively for AFP by immunohistochemistry. In these tumors more specifically, almost all cells stain for AFP.
Each dose that we chose for our cell lines was different, because these were the doses that were required to elicit mild to moderate cytotoxicity. Certain cells are more resistant to our virus, but this resistance can be overcome by increasing the viral dose. Without transduction the virus could kill tumors, but at much larger doses than were used in our experiment. So this allowed us to reduce the amount of virus used and ultimately the amount of cost for the treatment.
In response to the question regarding the bystander effect, there is potential for the bystander effect in our experiment. Not all cells could be transduced, although 90% of them are shown to be transduced in our experiment. But those cells that are not transduced or not infected with virus can still be lysed through this bystander effect. If the cell is infected with the virus and lysed.
In response to the question regarding the 2 controls which we have not presented, the albumin promoter which we had used is a minimal promoter. It has very weak activity on its own and will not further gene transcription. It will only function when paired with strong enhancers such as our AFP enhancer, which controls over 90% of inducible AFP gene expression.
This supports the safety and specificity of our construct to AFP-producing hepatoma. Furthermore, with response to the question regarding normal hepatocytes, these do not secrete AFP; therefore, it would be unresponsive to our vector and further supports our safety. There was one experiment by Dr. Tanabe several years ago which examined a virus similar to G207, and he showed that it preferentially infected hepatoma cells while sparing normal surrounding hepatocytes.
With response to the question regarding reinfection of our animal tumors, in our current experiments re-injection after our primary viral dose would have to be time dependent. Our transfection is stable only for 7 days. Therefore, if we gave a second dose of virus, it may reduce tumor burden within the first week and have a decreased tumor volume subsequently. After 7 days there would likely be no effect with reinfection because the transgene expression at that time would be diminished.
And answering the final question of where we would go from here, our experimental results encourage us to construct a recombinant G207 virus which would autonomously express our AFP-driven UL39. This would circumvent plasma transfection, the possibility for unstable gene expression, and allow for the treatment of established tumors. We would do this through homologous recombination with linearized G207 DNA and our construct between viral flanking sequences.
